Viatris, formed in 2020 through a merger of Mylan and Pfizer’s Upjohn division, is a global pharmaceutical company focused on providing access to high-quality medicines. Viatris aims to improve global healthcare by increasing access to affordable medications and healthcare solutions. The company’s portfolio includes a wide range of generic drugs, over-the-counter medications, biosimilars, and complex generic products. Viatris operates manufacturing facilities worldwide, ensuring the production and distribution of its diverse portfolio to patients in need. The company’s commitment to expanding access to healthcare is supported by its global presence and collaborations with various stakeholders, including healthcare providers, governments, and patient organizations.